217 related articles for article (PubMed ID: 29266186)
1. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
Vinay K; Yanamandra U; Dogra S; Handa S; Suri V; Kumari S; Khadwal A; Prakash G; Lad D; Varma S; Malhotra P
Int J Dermatol; 2018 Mar; 57(3):332-338. PubMed ID: 29266186
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Dervis E; Ayer M; Akin Belli A; Barut SG
Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
[TBL] [Abstract][Full Text] [Related]
3. Mucosal pigmentation of the hard palate in a patient taking imatinib.
Lyne A; Creedon A; Bailey BM
BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25883257
[TBL] [Abstract][Full Text] [Related]
4. Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature.
Di Tullio F; Mandel VD; Scotti R; Padalino C; Pellacani G
Int J Dermatol; 2018 Jul; 57(7):784-790. PubMed ID: 29417559
[TBL] [Abstract][Full Text] [Related]
5. Oral lichenoid reaction to imatinib (STI 571, Gleevec).
Lim DS; Muir J
Dermatology; 2002; 205(2):169-71. PubMed ID: 12218235
[TBL] [Abstract][Full Text] [Related]
6. Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.
Oliveira SR; de Azevedo Branco LG; Rocha AL; Travassos DV; Magalhães GHR; Fonseca FP; Mesquita RA; Abreu LG; da Silva TA
Clin Oral Investig; 2019 Dec; 23(12):4371-4382. PubMed ID: 30968242
[TBL] [Abstract][Full Text] [Related]
7. Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib.
Steele JC; Triantafyllou A; Rajlawat BP; Field EA
Clin Exp Dermatol; 2012 Jun; 37(4):432-3. PubMed ID: 22420895
[No Abstract] [Full Text] [Related]
8. Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
Paolino G; Didona D; Clerico R; Corsetti P; Ambrifi M; Bottoni U; Calvieri S
Cutis; 2016 Jun; 97(6):E12-6. PubMed ID: 27416091
[TBL] [Abstract][Full Text] [Related]
9. Oral lichenoid eruption associated with imatinib treatment.
Gómez Fernández C; Sendagorta Cudós E; Casado Verrier B; Feito Rodríguez M; Suárez Aguado J; Vidaurrázaga Díaz de Arcaya C
Eur J Dermatol; 2010; 20(1):127-8. PubMed ID: 19825526
[No Abstract] [Full Text] [Related]
10. Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib.
Lee WJ; Lee JH; Won CH; Chang SE; Choi JH; Moon KC; Kang YK; Lee MW
Int J Dermatol; 2016 May; 55(5):e268-74. PubMed ID: 26680344
[TBL] [Abstract][Full Text] [Related]
11. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
Lau YM; Lam YK; Leung KH; Lin SY
Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
[No Abstract] [Full Text] [Related]
12. Imatinib mesylate-induced lichenoid drug eruption.
Penn EH; Chung HJ; Keller M
Cutis; 2017 Mar; 99(3):189-192. PubMed ID: 28398413
[TBL] [Abstract][Full Text] [Related]
13. Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate.
Brazzelli V; Muzio F; Manna G; Moggio E; Vassallo C; Orlandi E; Fiandrino G; Lucioni M; Borroni G
Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):2-5. PubMed ID: 22211996
[TBL] [Abstract][Full Text] [Related]
14. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
Valeyrie L; Bastuji-Garin S; Revuz J; Bachot N; Wechsler J; Berthaud P; Tulliez M; Giraudier S
J Am Acad Dermatol; 2003 Feb; 48(2):201-6. PubMed ID: 12582389
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous manifestations in chronic myeloid leukemia in chronic phase treated with imatinib.
Khokar A; Malik U; Butt G; Naumeri F
Int J Dermatol; 2019 Sep; 58(9):1098-1101. PubMed ID: 31241173
[TBL] [Abstract][Full Text] [Related]
16. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
Kuraishi N; Nagai Y; Hasegawa M; Ishikawa O
Acta Derm Venereol; 2010; 90(1):73-6. PubMed ID: 20107730
[TBL] [Abstract][Full Text] [Related]
17. Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases.
Pascual JC; Matarredona J; Miralles J; Conesa V; Borras-Blasco J
Int J Dermatol; 2006 Dec; 45(12):1471-3. PubMed ID: 17184272
[No Abstract] [Full Text] [Related]
18. Imatinib-induced melanonychia in a patient of chronic myeloid leukaemia: rarely reported side effect.
Thapa M; Chaturvedi A
Postgrad Med J; 2020 May; 96(1135):296-297. PubMed ID: 31672761
[No Abstract] [Full Text] [Related]
19. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Shi CR; Nambudiri VE
Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
[No Abstract] [Full Text] [Related]
20. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia.
Deguchi N; Kawamura T; Shimizu A; Kitamura R; Yanagi M; Shibagaki N; Matsue H; Shimada S
Br J Dermatol; 2006 Jun; 154(6):1216-8. PubMed ID: 16704666
[No Abstract] [Full Text] [Related]
[Next] [New Search]
